-
Founded in:
2008-05-12 -
Country:
China -
Address:
122A Xianghuai Road, Benxi Economic Development Zone -
Tax NO.:
91210500673786474R -
Registered Funds:
110 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| L-(+)Sodium glutamate |
In severe hepatitis or liver dysfunction, the liver's conversion of ammonia to urea is impaired, resulting in increased blood ammonia and encephalopathy symptoms. The intake of glutamate and arginine is beneficial to reduce and eliminate blood ammonia, thereby improving encephalopathy symptoms.
More
In severe hepatitis or liver dysfunction, the liver's conversion of ammonia to urea is impaired, resulting in increased blood ammonia and encephalopathy symptoms. The intake of glutamate and arginine is beneficial to reduce and eliminate blood ammonia, thereby improving encephalopathy symptoms. |
142-47-2 | 4 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pasiniazid |
This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS effectively delays and blocks the acetylation process of INH in the body, enhances the bactericidal effect of the drug and delays the development of bacterial resistance. Clinically confirmed, in combination with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than INH, and the incidence of adverse reactions is significantly lower than INH. Animal experiments show that for artificially infected mice, the anti-tuberculosis efficacy of this product is about 5 times that of INH.
More
This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS effectively delays and blocks the acetylation process of INH in the body, enhances the bactericidal effect of the drug and delays the development of bacterial resistance. Clinically confirmed, in combination with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than INH, and the incidence of adverse reactions is significantly lower than INH. Animal experiments show that for artificially infected mice, the anti-tuberculosis efficacy of this product is about 5 times that of INH. |
2066-89-9 | 5 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Protionamide |
Extract from the above information
More
Extract from the above information |
14222-60-7 | 4 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium 4-aminosalicylate |
|
133-10-8 | 8 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium 4-aminosalicylate |
It has an antibacterial effect only on Mycobacterium tuberculosis. It inhibits the growth and reproduction of Mycobacterium tuberculosis by competitively inhibiting the synthesis of folic acid.
More
It has an antibacterial effect only on Mycobacterium tuberculosis. It inhibits the growth and reproduction of Mycobacterium tuberculosis by competitively inhibiting the synthesis of folic acid. |
95.0%-105.0%Label quantity | 133-10-8 | 8 |